<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="drugDebug/PMC7090474/results/search/disease/results.xml">
  <result pre="Sinica1674-07691995-820XSpringer SingaporeSingapore pmcid: 7090474207 doi: 10.1007/s12250-020-00207-4 : Review Understanding SARS-CoV-2-Mediated" exact="Inflammatory" post="Responses: From Mechanisms to Potential Therapeutic Tools http://orcid.org/0000-0002-4343-2220FuYajingfufu80s@sina.com12ChengYuanxiong3http://orcid.org/0000-0002-9547-3278WuYuntaoywu8@gmu.edu4[1], grid.412636.4NHC"/>
  <result pre="First Affiliated Hospital of China Medical University, [3], grid.413107.0Department of" exact="Respiratory" post="and Critical Care Medicine, The Third Affiliated Hospital of"/>
  <result pre="University, [4], grid.22448.380000 0004 1936 8032National Center for Biodefense and" exact="Infectious" post="Diseases, School of Systems Biology, George Mason University, epub:"/>
  <result pre="the PMC Open Access Subset for unrestricted research re-use and" exact="secondary" post="analysis in any form or by any means with"/>
  <result pre="SARS-CoV-2 infection, which frequently leads to fatal inflammatory responses and" exact="acute" post="lung injury. Here, we discuss the various mechanisms of"/>
  <result pre="responses include various methods to block FcR activation. In the" exact="absence of" post="a proven clinical FcR blocker, the use of intravenous"/>
  <result pre="may be a viable option for the urgent treatment of" exact="pulmonary" post="inflammation to prevent severe lung injury. Such treatment may"/>
  <result pre="severe lung injury. Such treatment may also be combined with" exact="systemic" post="anti-inflammatory drugs or corticosteroids. However, these strategies, as proposed"/>
  <result pre="here, remain to be clinically tested for effectiveness. Keywords SARS-CoV-2" exact="Inflammatory" post="response Fc receptors (FcR) Antibody-dependent enhancement (ADE) The newly"/>
  <result pre="receptors (FcR) Antibody-dependent enhancement (ADE) The newly emerging coronavirus, severe" exact="acute" post="respiratory syndrome coronavirus-2 (SARS-CoV-2), causes fatal acute respiratory disease"/>
  <result pre="(FcR) Antibody-dependent enhancement (ADE) The newly emerging coronavirus, severe acute" exact="respiratory" post="syndrome coronavirus-2 (SARS-CoV-2), causes fatal acute respiratory disease (ARD)"/>
  <result pre="Antibody-dependent enhancement (ADE) The newly emerging coronavirus, severe acute respiratory" exact="syndrome" post="coronavirus-2 (SARS-CoV-2), causes fatal acute respiratory disease (ARD) resembling"/>
  <result pre="emerging coronavirus, severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), causes fatal" exact="acute" post="respiratory disease (ARD) resembling that of SARS-CoV (Chen et"/>
  <result pre="coronavirus, severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), causes fatal acute" exact="respiratory" post="disease (ARD) resembling that of SARS-CoV (Chen et al.2020;"/>
  <result pre="severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), causes fatal acute respiratory" exact="disease" post="(ARD) resembling that of SARS-CoV (Chen et al.2020; Guan"/>
  <result pre="been well studied, but likely resembles that of SARS-CoV; the" exact="acute" post="lung injury caused by SARS-CoV infection mainly results from"/>
  <result pre="that of SARS-CoV; the acute lung injury caused by SARS-CoV" exact="infection" post="mainly results from aggressive inflammation initiated by viral replication"/>
  <result pre="by SARS-CoV infection mainly results from aggressive inflammation initiated by" exact="viral" post="replication (Wong et al.2004). Similar to SARS-CoV infection, SARS-CoV-2"/>
  <result pre="viral replication (Wong et al.2004). Similar to SARS-CoV infection, SARS-CoV-2" exact="infection" post="also causes increased secretion of IL-1β, IFN-γ, IP-10, MCP-1,"/>
  <result pre="with non-ICU (intensive care unit) patients, ICU patients with severe" exact="disease" post="had higher plasma levels of IL-2, IL-7, IL-10, GCSF,"/>
  <result pre="MIP-1A, and TNF-α, suggesting a possible cytokine storm associated with" exact="disease" post="severity (Huang et al.2020). Nevertheless, the causes of these"/>
  <result pre="Nevertheless, the causes of these exuberant inflammatory responses in SARS-CoV-2" exact="infection" post="remain largely unknown. In this review, we attempt to"/>
  <result pre="of SARS-CoV-2-mediated inflammatory responses (Fig. 1). In addition, given that" exact="uncontrolled" post="pulmonary inflammation is likely a leading cause of fatality"/>
  <result pre="SARS-CoV-2-mediated inflammatory responses (Fig. 1). In addition, given that uncontrolled" exact="pulmonary" post="inflammation is likely a leading cause of fatality in"/>
  <result pre="studies of SARS-CoV, we separate the inflammatory responses in SARS-CoV-2" exact="infection" post="into primary and secondary responses. Primary inflammatory responses occur"/>
  <result pre="SARS-CoV, we separate the inflammatory responses in SARS-CoV-2 infection into" exact="primary" post="and secondary responses. Primary inflammatory responses occur early after"/>
  <result pre="separate the inflammatory responses in SARS-CoV-2 infection into primary and" exact="secondary" post="responses. Primary inflammatory responses occur early after viral infection,"/>
  <result pre="inflammatory responses in SARS-CoV-2 infection into primary and secondary responses." exact="Primary" post="inflammatory responses occur early after viral infection, prior to"/>
  <result pre="primary and secondary responses. Primary inflammatory responses occur early after" exact="viral infection," post="prior to the appearance of neutralizing antibodies (NAb). These"/>
  <result pre="neutralizing antibodies (NAb). These responses are mainly driven by active" exact="viral" post="replication, viral-mediated ACE2 downregulation and shedding, and host anti-viral"/>
  <result pre="replication, viral-mediated ACE2 downregulation and shedding, and host anti-viral responses." exact="Secondary" post="inflammatory responses begin with the generation of adaptive immunity"/>
  <result pre="The virus-NAb complex can also trigger FcR-mediated inflammatory responses and" exact="acute" post="lung injury. Fig. 2 Fc receptor-mediated antibody-dependent enhancement (ADE)"/>
  <result pre="lung injury. Fig. 2 Fc receptor-mediated antibody-dependent enhancement (ADE) of" exact="viral infection" post="and inflammatory responses. A ADE occurs when antiviral neutralizing"/>
  <result pre="injury. Fig. 2 Fc receptor-mediated antibody-dependent enhancement (ADE) of viral" exact="infection" post="and inflammatory responses. A ADE occurs when antiviral neutralizing"/>
  <result pre="virus-NAb complex attaches to the Fc receptor (FcR), leading to" exact="viral" post="endocytosis and infection of the target cells. The outcome"/>
  <result pre="to the Fc receptor (FcR), leading to viral endocytosis and" exact="infection" post="of the target cells. The outcome is an increase"/>
  <result pre="increase in the overall replication of the virus and greater" exact="disease" post="severity. B Virus-NAb complex binding to FcR can also"/>
  <result pre="or inhibited competitively through IVIG binding. Inflammation Caused by Rapid" exact="Viral" post="Replication and Cellular Damage Previous studies have shown that"/>
  <result pre="studies have shown that SARS-CoV predominantly infects airway and alveolar" exact="epithelial" post="cells, vascular endothelial cells, and macrophages. In addition, SARS-CoV"/>
  <result pre="shown that SARS-CoV predominantly infects airway and alveolar epithelial cells," exact="vascular" post="endothelial cells, and macrophages. In addition, SARS-CoV viral particles"/>
  <result pre="epithelial cells, vascular endothelial cells, and macrophages. In addition, SARS-CoV" exact="viral" post="particles and viral genome have been detected in monocytes"/>
  <result pre="endothelial cells, and macrophages. In addition, SARS-CoV viral particles and" exact="viral" post="genome have been detected in monocytes and lymphocytes (Gu"/>
  <result pre="targeted and infected (Zhao et al.2020; Zhou et al.2020). The" exact="early onset" post="of rapid viral replication may cause massive epithelial and"/>
  <result pre="et al.2020; Zhou et al.2020). The early onset of rapid" exact="viral" post="replication may cause massive epithelial and endothelial cell apoptosis"/>
  <result pre="The early onset of rapid viral replication may cause massive" exact="epithelial" post="and endothelial cell apoptosis and vascular leakage, triggering the"/>
  <result pre="replication may cause massive epithelial and endothelial cell apoptosis and" exact="vascular" post="leakage, triggering the release of exuberant pro-inflammatory cytokines and"/>
  <result pre="exuberant pro-inflammatory cytokines and chemokines (Yang 2020). In addition, SARS-CoV-2" exact="infection" post="may also cause pyroptosis in macrophages and lymphocytes (Yang"/>
  <result pre="majority of patients (82.1%) have been found to experience SARS-CoV-2-induced" exact="peripheral" post="blood lymphopenia (Guan et al.2020), suggesting possible pulmonary infiltration"/>
  <result pre="patients (82.1%) have been found to experience SARS-CoV-2-induced peripheral blood" exact="lymphopenia" post="(Guan et al.2020), suggesting possible pulmonary infiltration of lymphocytes"/>
  <result pre="experience SARS-CoV-2-induced peripheral blood lymphopenia (Guan et al.2020), suggesting possible" exact="pulmonary" post="infiltration of lymphocytes and/or cell damage through apoptosis or"/>
  <result pre="and Shedding ACE2-associated lung injury has been suggested in SARS-CoV" exact="infection" post="(Imai et al.2008; Kuba et al.2005); SARS-CoV S protein"/>
  <result pre="et al.2008; Jia et al.2009; Lambert et al.2005). Loss of" exact="pulmonary" post="ACE2 function has been suggested to be associated with"/>
  <result pre="pulmonary ACE2 function has been suggested to be associated with" exact="acute" post="lung injury (Imai et al.2005, 2008; Kuba et al.2005,"/>
  <result pre="dysfunction of the renin-angiotensin system (RAS) and enhance inflammation and" exact="vascular" post="permeability. In a murine ARD model, loss of ACE2"/>
  <result pre="murine ARD model, loss of ACE2 expression resulted in enhanced" exact="vascular" post="permeability, increased lung edema, neutrophil accumulation, and diminished lung"/>
  <result pre="enzymatically active soluble ACE2 (sACE2) (Lambert et al.2005). Both SARS-CoV" exact="infection" post="and inflammatory cytokines such as IL-1β and TNF-α can"/>
  <result pre="to ACE2 to mediate NHL63-CoV entry (Haga et al.2008). HNL63-CoV" exact="infection" post="only causes the common cold, suggesting a potential pathogenic"/>
  <result pre="the inflammatory responses of SARS-CoV, and possibly SARS-CoV-2 as well." exact="Inflammatory" post="Responses Induced by Anti-Spike IgG (Anti-S-IgG) Antiviral neutralizing antibodies"/>
  <result pre="IgG (Anti-S-IgG) Antiviral neutralizing antibodies play an important role in" exact="viral" post="clearance. However, previous studies in animal models have shown"/>
  <result pre="severe lung injury; in these SARS-CoV S protein-vaccinated Chinese macaques," exact="acute" post="lung injury was more pronounced than in unvaccinated control"/>
  <result pre="in unvaccinated control animals that showed only minor to moderate" exact="lung inflammation" post="(Liu et al.2019). Consistent with this observation, adoptive transfer"/>
  <result pre="(i.v. injection) to macaques, despite the fact that it reduced" exact="viral" post="loads following subsequent challenge with SARS-CoVPUMC, led to acute"/>
  <result pre="reduced viral loads following subsequent challenge with SARS-CoVPUMC, led to" exact="acute" post="diffuse alveolar damage in all infected animals, whereas in"/>
  <result pre="viral loads following subsequent challenge with SARS-CoVPUMC, led to acute" exact="diffuse" post="alveolar damage in all infected animals, whereas in the"/>
  <result pre="observed (Liu et al.2019). This animal study suggests that despite" exact="viral" post="suppression, the presence of anti-spike protein antibody at the"/>
  <result pre="viral suppression, the presence of anti-spike protein antibody at the" exact="acute" post="stage of SARS-CoV infection can actually cause severe acute"/>
  <result pre="of anti-spike protein antibody at the acute stage of SARS-CoV" exact="infection" post="can actually cause severe acute lung injury that persists"/>
  <result pre="the acute stage of SARS-CoV infection can actually cause severe" exact="acute" post="lung injury that persists until the late stages. Similar"/>
  <result pre="persists until the late stages. Similar observations of SARS-CoV vaccine-induced" exact="pulmonary injury" post="have also been reported in multiple animal models using"/>
  <result pre="also been reported in multiple animal models using mice and" exact="African" post="green monkeys (Bolles et al.2011; Clay et al.2012; Tseng"/>
  <result pre="the clinical observations in SARS-CoV infected patients: the development of" exact="acute" post="respiratory disease coincides with antiviral IgG seroconversion in 80%"/>
  <result pre="clinical observations in SARS-CoV infected patients: the development of acute" exact="respiratory" post="disease coincides with antiviral IgG seroconversion in 80% of"/>
  <result pre="observations in SARS-CoV infected patients: the development of acute respiratory" exact="disease" post="coincides with antiviral IgG seroconversion in 80% of patients"/>
  <result pre="has been proposed that the presence of S-IgG prior to" exact="viral" post="clearance alters the functional polarization of alveolar macrophages in"/>
  <result pre="(ADCC) may also be involved. A major question in SARS-CoV-induced" exact="pulmonary disease" post="is why a small percentage of patients, particularly those"/>
  <result pre="may also be involved. A major question in SARS-CoV-induced pulmonary" exact="disease" post="is why a small percentage of patients, particularly those"/>
  <result pre="underlying mechanism may be related to antibody-dependent enhancement (ADE) of" exact="viral infection" post="that occurs in some patients with early, sub-optimal antibody"/>
  <result pre="mechanism may be related to antibody-dependent enhancement (ADE) of viral" exact="infection" post="that occurs in some patients with early, sub-optimal antibody"/>
  <result pre="cannot completely clear the virus, but instead leads to persistent" exact="viral" post="replication and inflammation (Fig. 2). ADE is a well-known"/>
  <result pre="a well-known virology phenomenon that has been demonstrated in the" exact="infections" post="of multiple viruses such as dengue, flavivirus, and influenza"/>
  <result pre="al.1992; Takada et al.2003; Takada and Kawaoka 2003). ADE promotes" exact="viral" post="cellular uptake of infectious virus-antibody complexes following their interaction"/>
  <result pre="Takada and Kawaoka 2003). ADE promotes viral cellular uptake of" exact="infectious" post="virus-antibody complexes following their interaction with FcR or other"/>
  <result pre="their interaction with FcR or other receptors, leading to enhanced" exact="infection" post="of target cells (Halstead and O’Rourke 1977; Haslwanter et"/>
  <result pre="the virus-anti-S-IgG complex may facilitate both inflammatory responses and persistent" exact="viral" post="replication in the lungs of some patients (Fig. 2)."/>
  <result pre="inflammatory responses in SARS-CoV infection, we focus only on discussing" exact="limited" post="mechanisms that might be involved. For the convenience of"/>
  <result pre="SARS-CoV-mediated inflammatory responses into two different stages (Fig. 1): the" exact="primary" post="response and the secondary response. Primary inflammatory responses occur"/>
  <result pre="two different stages (Fig. 1): the primary response and the" exact="secondary" post="response. Primary inflammatory responses occur early after viral infection,"/>
  <result pre="stages (Fig. 1): the primary response and the secondary response." exact="Primary" post="inflammatory responses occur early after viral infection, prior to"/>
  <result pre="and the secondary response. Primary inflammatory responses occur early after" exact="viral infection," post="prior to the appearance of neutralizing antibodies (NAb). These"/>
  <result pre="neutralizing antibodies (NAb). These responses are mainly driven by active" exact="viral" post="replication, viral-mediated ACE2 downregulation and shedding, and host antiviral"/>
  <result pre="cellular damage through apoptosis and/or pyroptosis. Most patients can tolerate" exact="primary" post="inflammatory responses with a positive outcome of viral load"/>
  <result pre="can tolerate primary inflammatory responses with a positive outcome of" exact="viral" post="load reduction or even viral clearance, followed by receding"/>
  <result pre="with a positive outcome of viral load reduction or even" exact="viral" post="clearance, followed by receding of inflammation. Secondary inflammatory responses"/>
  <result pre="reduction or even viral clearance, followed by receding of inflammation." exact="Secondary" post="inflammatory responses begin with the generation of adaptive immunity"/>
  <result pre="adaptive immunity and the appearance of NAb that further diminish" exact="viral" post="replication. However, as described above, the appearance of NAb"/>
  <result pre="the appearance of antiviral IgG coincides with the onset of" exact="acute" post="respiratory disease in 80% of patients (Peiris et al.2003)."/>
  <result pre="appearance of antiviral IgG coincides with the onset of acute" exact="respiratory" post="disease in 80% of patients (Peiris et al.2003). A"/>
  <result pre="of antiviral IgG coincides with the onset of acute respiratory" exact="disease" post="in 80% of patients (Peiris et al.2003). A possible"/>
  <result pre="A possible underlying mechanism is likely antibody-dependent enhancement (ADE) of" exact="viral infection" post="that leads to persistent viral replication and inflammatory responses"/>
  <result pre="possible underlying mechanism is likely antibody-dependent enhancement (ADE) of viral" exact="infection" post="that leads to persistent viral replication and inflammatory responses"/>
  <result pre="antibody-dependent enhancement (ADE) of viral infection that leads to persistent" exact="viral" post="replication and inflammatory responses from macrophages. Given that most"/>
  <result pre="inflammatory responses from macrophages. Given that most patients can survive" exact="primary" post="inflammatory responses, we mainly focus on discussing secondary inflammatory"/>
  <result pre="can survive primary inflammatory responses, we mainly focus on discussing" exact="secondary" post="inflammatory responses that frequently lead to fatality. There are"/>
  <result pre="Third, FcR activation can also be inhibited by targeting the" exact="neonatal" post="Fc receptor (FcRn), which is essential for extending the"/>
  <result pre="(FcRn), which is essential for extending the half-life of IgG." exact="Antibody" post="or small molecule-mediated blockage of FcRn can prevent IgG"/>
  <result pre="SARS-CoV-2 infection, which frequently leads to fatal inflammatory responses and" exact="acute" post="lung injury. Here, we discuss the various mechanisms of"/>
  <result pre="responses include various methods to block FcR activation. In the" exact="absence of" post="a proven clinical FcR blocker, the use of intravenous"/>
  <result pre="may be a viable option for the urgent treatment of" exact="pulmonary" post="inflammation to prevent severe lung injury. Such treatment may"/>
  <result pre="severe lung injury. Such treatment may also be combined with" exact="systemic" post="anti-inflammatory drugs or corticosteroids. However, these strategies, as proposed"/>
  <result pre="by any of the authors. References References BollesMDemingDLongKAgnihothramSWhitmoreAFerrisMFunkhouserWGralinskiLToturaAHeiseMBaricRSA double-inactivated severe" exact="acute" post="respiratory syndrome coronavirus vaccine provides incomplete protection in mice"/>
  <result pre="any of the authors. References References BollesMDemingDLongKAgnihothramSWhitmoreAFerrisMFunkhouserWGralinskiLToturaAHeiseMBaricRSA double-inactivated severe acute" exact="respiratory" post="syndrome coronavirus vaccine provides incomplete protection in mice and"/>
  <result pre="of the authors. References References BollesMDemingDLongKAgnihothramSWhitmoreAFerrisMFunkhouserWGralinskiLToturaAHeiseMBaricRSA double-inactivated severe acute respiratory" exact="syndrome" post="coronavirus vaccine provides incomplete protection in mice and induces"/>
  <result pre="References BollesMDemingDLongKAgnihothramSWhitmoreAFerrisMFunkhouserWGralinskiLToturaAHeiseMBaricRSA double-inactivated severe acute respiratory syndrome coronavirus vaccine provides" exact="incomplete" post="protection in mice and induces increased eosinophilic proinflammatory pulmonary"/>
  <result pre="coronavirus vaccine provides incomplete protection in mice and induces increased" exact="eosinophilic" post="proinflammatory pulmonary response upon challengeJ Virol201185122011221510.1128/JVI.06048-1121937658 ChenIYMoriyamaMChangMFIchinoheTSevere acute respiratory"/>
  <result pre="provides incomplete protection in mice and induces increased eosinophilic proinflammatory" exact="pulmonary" post="response upon challengeJ Virol201185122011221510.1128/JVI.06048-1121937658 ChenIYMoriyamaMChangMFIchinoheTSevere acute respiratory syndrome coronavirus"/>
  <result pre="induces increased eosinophilic proinflammatory pulmonary response upon challengeJ Virol201185122011221510.1128/JVI.06048-1121937658 ChenIYMoriyamaMChangMFIchinoheTSevere" exact="acute" post="respiratory syndrome coronavirus viroporin 3a activates the NLRP3 inflammasomeFront"/>
  <result pre="increased eosinophilic proinflammatory pulmonary response upon challengeJ Virol201185122011221510.1128/JVI.06048-1121937658 ChenIYMoriyamaMChangMFIchinoheTSevere acute" exact="respiratory" post="syndrome coronavirus viroporin 3a activates the NLRP3 inflammasomeFront Microbiol2019105010.3389/fmicb.2019.0005030761102"/>
  <result pre="eosinophilic proinflammatory pulmonary response upon challengeJ Virol201185122011221510.1128/JVI.06048-1121937658 ChenIYMoriyamaMChangMFIchinoheTSevere acute respiratory" exact="syndrome" post="coronavirus viroporin 3a activates the NLRP3 inflammasomeFront Microbiol2019105010.3389/fmicb.2019.0005030761102 ChenNZhouMDongXQuJGongFHanYQiuYWangJLiuYWeiYXiaJYuTZhangXZhangLEpidemiological"/>
  <result pre="ChenNZhouMDongXQuJGongFHanYQiuYWangJLiuYWeiYXiaJYuTZhangXZhangLEpidemiological and clinical characteristics of 99 cases of 2019 novel" exact="coronavirus pneumonia" post="in Wuhan, China: a descriptive studyLancet202010.1016/S0140-6736(20)30211-732112738 ClayCDonartNFomukongNKnightJBLeiWPriceLHahnFVan WestrienenJHarrodKSPrimary severe"/>
  <result pre="and clinical characteristics of 99 cases of 2019 novel coronavirus" exact="pneumonia" post="in Wuhan, China: a descriptive studyLancet202010.1016/S0140-6736(20)30211-732112738 ClayCDonartNFomukongNKnightJBLeiWPriceLHahnFVan WestrienenJHarrodKSPrimary severe"/>
  <result pre="pneumonia in Wuhan, China: a descriptive studyLancet202010.1016/S0140-6736(20)30211-732112738 ClayCDonartNFomukongNKnightJBLeiWPriceLHahnFVan WestrienenJHarrodKSPrimary severe" exact="acute" post="respiratory syndrome coronavirus infection limits replication but not lung"/>
  <result pre="in Wuhan, China: a descriptive studyLancet202010.1016/S0140-6736(20)30211-732112738 ClayCDonartNFomukongNKnightJBLeiWPriceLHahnFVan WestrienenJHarrodKSPrimary severe acute" exact="respiratory" post="syndrome coronavirus infection limits replication but not lung inflammation"/>
  <result pre="Wuhan, China: a descriptive studyLancet202010.1016/S0140-6736(20)30211-732112738 ClayCDonartNFomukongNKnightJBLeiWPriceLHahnFVan WestrienenJHarrodKSPrimary severe acute respiratory" exact="syndrome" post="coronavirus infection limits replication but not lung inflammation upon"/>
  <result pre="China: a descriptive studyLancet202010.1016/S0140-6736(20)30211-732112738 ClayCDonartNFomukongNKnightJBLeiWPriceLHahnFVan WestrienenJHarrodKSPrimary severe acute respiratory syndrome" exact="coronavirus infection" post="limits replication but not lung inflammation upon homologous rechallengeJ"/>
  <result pre="a descriptive studyLancet202010.1016/S0140-6736(20)30211-732112738 ClayCDonartNFomukongNKnightJBLeiWPriceLHahnFVan WestrienenJHarrodKSPrimary severe acute respiratory syndrome coronavirus" exact="infection" post="limits replication but not lung inflammation upon homologous rechallengeJ"/>
  <result pre="severe acute respiratory syndrome coronavirus infection limits replication but not" exact="lung inflammation" post="upon homologous rechallengeJ Virol2012864234424410.1128/JVI.06791-1122345460 FinkSLCooksonBTApoptosis, pyroptosis, and necrosis: mechanistic"/>
  <result pre="GlowackaIBertramSHerzogPPfefferleSSteffenIMuenchMOSimmonsGHofmannHKuriTWeberFEichlerJDrostenCPöhlmannSDifferential downregulation of ACE2 by the spike proteins of severe" exact="acute" post="respiratory syndrome coronavirus and human coronavirus NL63J Virol2010841198120510.1128/JVI.01248-0919864379 GuJGongEZhangBZhengJGaoZZhongYZouWZhanJWangSXieZZhuangHWuBZhongHShaoHFangWGaoDPeiFLiXHeZXuDShiXAndersonVMLeongASMultiple"/>
  <result pre="downregulation of ACE2 by the spike proteins of severe acute" exact="respiratory" post="syndrome coronavirus and human coronavirus NL63J Virol2010841198120510.1128/JVI.01248-0919864379 GuJGongEZhangBZhengJGaoZZhongYZouWZhanJWangSXieZZhuangHWuBZhongHShaoHFangWGaoDPeiFLiXHeZXuDShiXAndersonVMLeongASMultiple organ"/>
  <result pre="of ACE2 by the spike proteins of severe acute respiratory" exact="syndrome" post="coronavirus and human coronavirus NL63J Virol2010841198120510.1128/JVI.01248-0919864379 GuJGongEZhangBZhengJGaoZZhongYZouWZhanJWangSXieZZhuangHWuBZhongHShaoHFangWGaoDPeiFLiXHeZXuDShiXAndersonVMLeongASMultiple organ infection"/>
  <result pre="respiratory syndrome coronavirus and human coronavirus NL63J Virol2010841198120510.1128/JVI.01248-0919864379 GuJGongEZhangBZhengJGaoZZhongYZouWZhanJWangSXieZZhuangHWuBZhongHShaoHFangWGaoDPeiFLiXHeZXuDShiXAndersonVMLeongASMultiple organ" exact="infection" post="and the pathogenesis of SARSJ Exp Med200520241542410.1084/jem.2005082816043521 GuanWJNiZYHuYLiangWHOuCHeJLiuLShanHLeiCHuiDSCet al.Clinical"/>
  <result pre="of SARSJ Exp Med200520241542410.1084/jem.2005082816043521 GuanWJNiZYHuYLiangWHOuCHeJLiuLShanHLeiCHuiDSCet al.Clinical characteristics of 2019 novel" exact="coronavirus infection" post="in ChinaMedRxiv202010.1101/2020.02.06.20020974 HagaSYamamotoNNakai-MurakamiCOsawaYTokunagaKSataTYamamotoNSasazukiTIshizakaYModulation of TNF-alpha-converting enzyme by the spike"/>
  <result pre="SARSJ Exp Med200520241542410.1084/jem.2005082816043521 GuanWJNiZYHuYLiangWHOuCHeJLiuLShanHLeiCHuiDSCet al.Clinical characteristics of 2019 novel coronavirus" exact="infection" post="in ChinaMedRxiv202010.1101/2020.02.06.20020974 HagaSYamamotoNNakai-MurakamiCOsawaYTokunagaKSataTYamamotoNSasazukiTIshizakaYModulation of TNF-alpha-converting enzyme by the spike"/>
  <result pre="protein of SARS-CoV and ACE2 induces TNF-alpha production and facilitates" exact="viral" post="entryProc Natl Acad Sci U S A20081057809781410.1073/pnas.071124110518490652 HalsteadSBO’RourkeEJAntibody-enhanced dengue"/>
  <result pre="viral entryProc Natl Acad Sci U S A20081057809781410.1073/pnas.071124110518490652 HalsteadSBO’RourkeEJAntibody-enhanced dengue" exact="virus infection" post="in primate leukocytesNature197726573974110.1038/265739a0404559 HaslwanterDBlaasDHeinzFXStiasnyKA novel mechanism of antibody-mediated enhancement"/>
  <result pre="entryProc Natl Acad Sci U S A20081057809781410.1073/pnas.071124110518490652 HalsteadSBO’RourkeEJAntibody-enhanced dengue virus" exact="infection" post="in primate leukocytesNature197726573974110.1038/265739a0404559 HaslwanterDBlaasDHeinzFXStiasnyKA novel mechanism of antibody-mediated enhancement"/>
  <result pre="coronavirus in WuhanLancet China202010.1016/S0140-6736(20)30183-5 ImaiYKubaKRaoSHuanYGuoFGuanBYangPSaraoRWadaTLeong-PoiHCrackowerMAFukamizuAHuiCCHeinLUhligSSlutskyASJiangCPenningerJMAngiotensin-converting enzyme 2 protects from severe" exact="acute" post="lung failureNature200543611211610.1038/nature0371216001071 ImaiYKubaKPenningerJMThe discovery of angiotensin-converting enzyme 2 and"/>
  <result pre="ImaiYKubaKPenningerJMThe discovery of angiotensin-converting enzyme 2 and its role in" exact="acute" post="lung injury in miceExp Physiol20089354354810.1113/expphysiol.2007.04004818448662 JiaHPLookDCTanPShiLHickeyMGakharLChappellMCWohlford-LenaneCMcCrayPBJrEctodomain shedding of angiotensin"/>
  <result pre="factor-alpha convertase (ADAM17) mediates regulated ectodomain shedding of the severe-acute" exact="respiratory" post="syndrome-coronavirus (SARS-CoV) receptor, angiotensin-converting enzyme-2 (ACE2)J Biol Chem2005280301133011910.1074/jbc.M50511120015983030 LiuLWeiQLinQFangJWangHKwokHTangHNishiuraKPengJTanZWuTCheungKWChanKHAlvarezXQinCLacknerAPerlmanSYuenKYChenZAnti-spike"/>
  <result pre="receptor, angiotensin-converting enzyme-2 (ACE2)J Biol Chem2005280301133011910.1074/jbc.M50511120015983030 LiuLWeiQLinQFangJWangHKwokHTangHNishiuraKPengJTanZWuTCheungKWChanKHAlvarezXQinCLacknerAPerlmanSYuenKYChenZAnti-spike IgG causes severe" exact="acute" post="lung injury by skewing macrophage responses during acute SARS-CoV"/>
  <result pre="causes severe acute lung injury by skewing macrophage responses during" exact="acute" post="SARS-CoV infectionJCI Insight201910.1172/jci.insight.12315831852848 NimmerjahnFRavetchJVAnalyzing antibody-Fc-receptor interactionsMethods Mol Biol200841515116218370153 NimmerjahnFRavetchJVAnti-inflammatory"/>
  <result pre="Rev Immunol20088344710.1038/nri220618064051 OchiaiHKurokawaMMatsuiSYamamotoTKurokiYKishimotoCShirakiKInfection enhancement of influenza A NWS virus in" exact="primary" post="murine macrophages by anti-hemagglutinin monoclonal antibodyJ Med Virol19923621722110.1002/jmv.18903603121564451 PeirisJSChuCMChengVCChanKSHungIFPoonLLLawKITangBSHonTYChanCSChanKHNgJSZhengBJNgWLLaiRWGuanYYuenKYcollab:"/>
  <result pre="antibodyJ Med Virol19923621722110.1002/jmv.18903603121564451 PeirisJSChuCMChengVCChanKSHungIFPoonLLLawKITangBSHonTYChanCSChanKHNgJSZhengBJNgWLLaiRWGuanYYuenKYcollab: HKU/UCH SARS Study GroupClinical progression and" exact="viral" post="load in a community outbreak of coronavirus-associated SARS pneumonia:"/>
  <result pre="of coronavirus-associated SARS pneumonia: a prospective studyLancet20033611767177210.1016/S0140-6736(03)13412-512781535 TakadaAKawaokaYAntibody-dependent enhancement of" exact="viral" post="infection: molecular mechanisms and in vivo implicationsRev Med Virol20031338739810.1002/rmv.40514625886"/>
  <result pre="virus infectionJ Virol2003777539754410.1128/JVI.77.13.7539-7544.200312805454 TsengCTSbranaEIwata-YoshikawaNNewmanPCGarronTAtmarRLPetersCJCouchRBImmunization with SARS coronavirus vaccines leads to" exact="pulmonary" post="immunopathology on challenge with the SARS virusPLoS ONE20127e3542110.1371/journal.pone.003542122536382 van"/>
  <result pre="receptor ACE2Virus Res200813681510.1016/j.virusres.2008.03.00418554741 WongCKLamCWWuAKIpWKLeeNLChanIHLitLCHuiDSChanMHChungSSSungJJPlasma inflammatory cytokines and chemokines in severe" exact="acute" post="respiratory syndromeClin Exp Immunol20041369510310.1111/j.1365-2249.2004.02415.x15030519 YangMCell pyroptosis, a potential pathogenic"/>
  <result pre="ACE2Virus Res200813681510.1016/j.virusres.2008.03.00418554741 WongCKLamCWWuAKIpWKLeeNLChanIHLitLCHuiDSChanMHChungSSSungJJPlasma inflammatory cytokines and chemokines in severe acute" exact="respiratory" post="syndromeClin Exp Immunol20041369510310.1111/j.1365-2249.2004.02415.x15030519 YangMCell pyroptosis, a potential pathogenic mechanism"/>
  <result pre="2019-nCoV infectionSSRN202010.2139/ssrn.3527420 ZhangLZhangFYuWHeTYuJYiCEBaLLiWFarzanMChenZYuenKYHoDAntibody responses against SARS coronavirus are correlated with" exact="disease" post="outcome of infected individualsJ Med Virol2006781810.1002/jmv.2049916299724 ZhaoYZhaoZWangYZhouYMaYZouWSingle-Cell RNA expression"/>
  <result pre="profiling of ACE2, the putative receptor of Wuhan 2019-nCoVBioRxi202010.1101/2020.01.26.919985 ZhouPYangXLWangXGHuBZhangLZhangWSiHRZhuYLiBHuangCLChenHDChenJLuoYGuoHJiangRDLiuMQChenYShenXRWangXZhengXSZhaoKChenQJDengFLiuLLYanBZhanFXWangYYXiaoGFShiZLA" exact="pneumonia" post="outbreak associated with a new coronavirus of probable bat"/>
 </snippets>
</snippetsTree>
